Educational Objectives

 Discuss the pathogenesis of diabetic dyslipidemia.

 Explain the mechanisms of lipoprotein metabolism.

 Discuss clinical trial data in patients with diabetic dyslipidemia including
 the Diabetes Atherosclerosis Intervention Study (DAIS), the Helsinki
 Heart Study (HHS); and the Bezafibrate Intervention Project (BIP).

 Select appropriate medical management for patients with diabetic
 dyslipidemia with drug therapy including fibrates and statins.
 Discuss statin-fibrate pharmacokinetics and safety issues.

Subject Content

 Lipoprotein metabolism.

 Pharmacokinetics of statins and fibrates and related safety issues.

 Utilization of NCEP ATP III guidelines in the assessment of global
 risk for CHD.

 Clinical trials of fibrates and statins in patients with diabetic dyslipidemia.

 Proper utilization of the revised NCEP ATP III guidelines and the ADA
 guidelines for proper management of patients with diabetic dyslipidemia.

This edition is for information and study purposes only as the
CME credits have expired.

Back to Complex Lipid Management